Three CAR-T therapies to capture over 70% of T-Cell immunotherapy market

5 May 2025

T-cell immunotherapies (TCI) are redefining cancer care, with chimeric antigen receptor T-cell (CAR-T) therapies witnessing significant momentum.

In 2025, just three drugs - Carvykti (ciltacabtagene autoleucel) from Legend Biotech (Nasdaq: LEGN), Yescarta (axicabtagene ciloleucel) from Gilead Sciences (Nasdaq: GILD) and Breyanzi (ciltacabtagene autoleucel) by Bristol Myers Squibb (NYSE: BMY) - are expected to capture over 70% of the global T-cell immunotherapy market, according to pharma analytics company GlobalData.

GlobalData’s latest report, “T-Cell Immunotherapy Landscape: Comprehensive Analysis of Current Drugs and Dynamics,” reveals that the TCI space is entering a new growth phase, driven by clinical success and investor confidence. Sales are forecast to double between 2024 and 2027, as CAR-T therapies continue expanding beyond blood cancers into solid tumors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK